1. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol. 2000;74:1961–72. [PMC free article] [PubMed] 2. Weiss CD, Levy JA, White JM. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol. 1990;64:5674–77. [PMC free article] [PubMed] 3. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997;89:263–73. [PubMed] 4. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med. 1990;112:247–53. [PubMed] 5. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A. 1990;87:6574–78. [PubMed] 6. Turner S, Tizard R, DeMarinis J, Pepinsky B, Zullo J, Schooley R, et al. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1992;89:1335–39. [PubMed] 7. Davey RT, Jr., Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathen L, et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis. 1994;170:1180–1188. [PubMed] 8. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses. 1995;11:533–39. [PubMed] 9. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004;48:423–29. [PMC free article] [PubMed] 10. Guo Q, Ho HT, Dicker I, Fan L, Zhou N, Friborg J, et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol. 2003;77:10528–36. [PMC free article] [PubMed] 11. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A. 2003;100:11013–18. [PubMed]
12. Hanna G, Lalezari J, Hellinger J, Wohl D, Masterson T, Fiske W, et al. Antiviral activity, safety and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects; Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA. February 8-11, 2004; Abstract 141.
13. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol. 1992;149:1779–87. [PubMed] 14. Burkly L, Mulrey N, Blumenthal R, Dimitrov DS. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J Virol. 1995;69:4267–73. [PMC free article] [PubMed] 15. Zhang XQ, Sorensen M, Fung M, Schooley RT. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20) Antimicrob Agents Chemother. 2006;50:2231–33. [PMC free article] [PubMed] 16. Boon L, Holland B, Gordon W, Liu P, Shiau F, Shanahan W, et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology. 2002;172:191–203. [PubMed] 17. Reimann KA, Lin W, Bixler S, Browning B, Ehrenfels BN, Lucci J, et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses. 1997;13:933–43. [PubMed] 18. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with human immunodeficiency virus type 1. J Infect Dis. 2004;189:286–91. [PubMed]
19. Jacobson J, Kuritzkes DR, Godofsky E, DeJesus E, Lewis S, Jackson J, et al. Phase 1b Study of the anti- CD4 monoclonal antibody TNX-355 in HIV-1-infected subjects: safety and antiretroviral activity of multiple doses; Program and Abstsracts of the 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA. February 8-11, 2004; Abstract 536.
20. Norris D, Morales J, Gathe J, Godofsky E, Garcia F, Hardwicke R, et al. Phase 2 efficacy and safety of the novel entry inhibitor, TNX-355, in combinatio nwith optimized background regimen (OBR); Programme & Abstracts of the XVI International AIDS Conference; Toronto, ON, Canada. August 13-18 2006; Abstract THLB0218.
21. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis. 2005;191:866–72. [PubMed] 22. Melby T, Despirito M, DeMasi R, Heilek-Snyder G, Greenberg ML, Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis. 2006;194:238–46. [PubMed] 23. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192:466–74. [PubMed] 24. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis. 2008;46:1617–23. [PubMed]** Demonstrates compelling evidence for an association between presence of CXCR4-using virus and risk of CD4 decline. First paper to do so using contemporary tropism assays in an untreated cohort. 25. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol. 2005;67:1268–82. [PubMed] 26. Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS. 2005;19:1443–48. [PubMed] 27. Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) Antimicrob Agents Chemother. 2008;52:858–65. [PubMed]** Details the hepatotoxicity observed during aplaviroc studies and why development of this drug was stopped.
28. Cohen C, DeJesus E, Mills A, Pierone G, Kumar P, Ruane P, et al. Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days monotherapy; 4th IAS Conference on AIDS Pathogenesis, Treatment and Prevention; Sydney, Australia. 22-25 July 2007; Abstract TUAB106.
29. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49:4721–32. [PMC free article] [PubMed] 30. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170–1172. [PubMed] 31. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–41. [PubMed]**Primary results of the pivotal phase 3 clinical trials with maraviroc that led to FDA approval of this drug (see also reference 32). 32. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442–55. [PubMed]**Provides many of the supportive secondary analyses conducted in the pivotal phase 3 trials of maraviroc (companion paper to reference 31).
33. Goodrich JM, Saag M, van der Ryst E, Fatkenheuer G, Clotet B, Clumeck N, et al. 48-week safety and eficacy of maraviroc, a novel CCR5 antagonist, in combination with optimized background therapy (OBT) for the treatent of antiretroviral-experienced patients infected with dual/mixed-tropic HIV-1; Program & Abstracts of the 45th Annual Meeting of the Infectious Disease Society of America; San Diego, CA. October 4-7, 2007; Abstract LB-2.
34. Saag M, Ive P, Heera J, Tawadrous M, DeJesus E, Clumeck N, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV-1: Week 48 results of the MERIT study; 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney, Australia. 22-25 July, 2007; Abstract WESS104.
35. Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49:4911–19. [PMC free article] [PubMed] 36. Schurmann D, Fatkenheuer G, Reynes J, Michelet C, Raffi F, van Lier J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS. 2007;21:1293–99. [PubMed]*Results of the initial proof-of-concept study with vicriviroc. 37. Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, et al. Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-Naive Subjects with HIV-1 Infection. J Infect Dis. 2008;198:1113–22. [PubMed]*Reports results of the terminated phase 2b trial of vicriviroc in treatment-naïve subjects. 38. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007;196:304–12. [PubMed]*Demonstrates durable viral suppression in treatment-experienced patients receiving vicriviroc.
39. Gulick R, Su Z, Flexner C, Hughes M, Skolnik P, Godfrey C, et al. ACTG A5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 results; 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney, Australia. 22-25 July, 2007; Abstract TUAB102.
40. Zingman B, Suleiman J, DeJesus E, Slim J, McCarthy M, Lee E, et al. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppressino of viral replication in treatment-experienced adults: VICTOR-E1 48-week results; Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA. February 3-6, 2008; 2008. Abstract 795.
41. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, et al. Chemokine coreceptor tropism among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trials Group A5211. Clin Infect Dis. 2007;44:591–95. [PubMed]*Cross-sectional analysis of the prevalence of CCR5-, CXCR4- and dual-tropic viruses in a highly treatment-experienced cohort. 42. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs AE, Redpath E, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000;44:1667–73. [PMC free article] [PubMed] 43. Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol. 2005;114:198–205. [PubMed]
44. Saag M, Rosenkranz S, Becker S, Klingman K, Zadzilka A, Coakley E, et al. Proof of concept of antiretroviral activity of AMD11070 (an orally administered CXCR4 entry inhibitor): Results of the irst dosing cohort A studied in ACTG protocol A5210; Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA. February 3-6, 2008; Abstract 512.
45. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994;91:9770–9774. [PubMed] 46. Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–85. [PubMed] 47. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–95. [PubMed] 48. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–78. [PubMed]*Illustrates significant contribution of enfuvirtide to virologic success of tipranavir-based regimens in treatment-experienced patients. 49. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466–75. [PubMed]